Acasă › Neuroblastom › Massachusetts
Studii clinice pentru Neuroblastom în Massachusetts
13 studii pentru Neuroblastom caută participanți în Massachusetts.
Orașe în Massachusetts
Text oficial al studiului (în engleză)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
În curs de recrutareFaza 3
Până la vârsta de 30 · Toate sexele · Actualizat 2 oct. 2026 · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- Brigham and Women's Hospital, Boston
În curs de recrutare
Toate vârstele · Toate sexele · Actualizat 1 oct. 2026 · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
În curs de recrutareFaza 1/2
6 Months – 25 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT06395103B7-H3.CD28Z.CART in Solid Tumors
- Dana Farber Cancer Institite, Boston
În curs de recrutareFaza 1
9 Months – 30 Years · Toate sexele · Actualizat 3 sept. 2026 · NCT07358260Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
În curs de recrutareFaza 3
365 Days – 30 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
În curs de recrutareFaza 1/2
12 Months – 30 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT04851119SPEARHEAD-3 Pediatric Study
- Dana Farber Cancer Institute, Boston
În curs de recrutareFaza 1/2
Vârste de la 2 la 21 · Toate sexele · Actualizat 11 aug. 2026 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
În curs de recrutareFaza 1/2
Vârste de la 1 la 30 · Toate sexele · Actualizat 22 iul. 2026 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Boston Children's Hospital, Dana-Farber Cancer Institute., Boston
În curs de recrutareFaza 2
Vârste de la 1 la 31 · Toate sexele · Actualizat 20 iul. 2026 · NCT06450041Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
În curs de recrutareFaza 1
Vârste de la 1 la 30 · Toate sexele · Actualizat 14 iul. 2026 · NCT07027748Neuroblastoma Biology Study
- Children's Hospital Boston, Boston
În curs de recrutareStudiu observațional
31 Days – 99 Years · Toate sexele · Actualizat 23 mar. 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Dana-Farber Cancer Institute, Boston
În curs de recrutare
Până la vârsta de 17 · Toate sexele · Actualizat 10 feb. 2026 · NCT06831552Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
În curs de recrutareFaza 1/2
12 Months – 29 Years · Toate sexele · Actualizat 26 dec. 2025 · NCT06803875Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.